관상동맥 질환 진단 영상 시장 규모, 점유율 및 동향 분석 보고서 : 모달리티별, 지역별 및 부문별 예측(2026-2033년)

Coronary Heart Disease Diagnostic Imaging Market Summary

The global coronary heart disease diagnostic imaging market size was estimated at USD 4.67 billion in 2025 and is projected to reach USD 7.73 billion by 2033, growing at a CAGR of 6.5% from 2026 to 2033. Growth is driven by the rising prevalence of cardiovascular diseases, increasing adoption of advanced imaging technologies such as CT, MRI, and nuclear imaging, and growing awareness of early diagnosis.

In addition, aging populations and lifestyle-related risk factors are fueling demand for accurate and non-invasive diagnostic solutions. Technological advancements, including AI integration and improved imaging accuracy, are further supporting market expansion, enabling better clinical outcomes and enhancing the efficiency of cardiovascular disease management worldwide.

One of the main factors driving the market expansion for coronary heart disease diagnostic imaging devices is the rising incidence of coronary artery diseases (CAD) worldwide. With nearly 19.8 million deaths per year, cardiovascular diseases continue to be the leading cause of death globally, with coronary heart disease accounting for a sizable portion of these deaths. Coronary artery disease (CAD) is primarily caused by atherosclerosis, which leads to the narrowing or blockage of coronary arteries. The demand for diagnostic imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), echocardiography, and coronary angiography have directly increased due to the increasing number of patients at risk.

Moreover, demographic changes, especially population aging, have led to a marked increase in the prevalence of CAD. The incidence of coronary conditions is higher in older populations because they are more vulnerable to atherosclerotic changes. For instance, compared to younger populations, prevalence rates are significantly higher among those over 65, underscoring age as a crucial risk factor. Furthermore, a greater number of patients have chronic cardiovascular conditions because of longer life expectancies worldwide, which has increased the use of diagnostic imaging technologies over time.

Global Coronary Heart Disease Diagnostic Imaging Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global coronary heart disease diagnostic imaging market report based on modality and region:

• Modality Outlook (Revenue, USD Million, 2021 - 2033)
• Computed Tomography
• X rays
• Ultrasound
• Magnetic Resonance Imaging
• Nuclear Medicine
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Modality
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Modality Segment
  • 2.2.2. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Coronary Heart Disease Diagnostic Imaging Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of coronary artery diseases
    • 3.2.1.2. Rising adoption of early diagnostic techniques
    • 3.2.1.3. Technological advancements in cardiac imaging modalities
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of skilled radiologists
    • 3.2.2.2. High costs of medical imaging systems
• 3.3. Coronary Heart Disease Diagnostic Imaging Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Coronary Heart Disease Diagnostic Imaging Market: Modality Estimates & Trend Analysis

• 4.1. Coronary Heart Disease Diagnostic Imaging Market: Modality Dashboard
• 4.2. Coronary Heart Disease Diagnostic Imaging Market: Modality Movement Analysis
• 4.3. Coronary Heart Disease Diagnostic Imaging Market Size & Forecasts and Trend Analysis, by Modality, 2021 to 2033 (USD Million)
• 4.4. Computed Tomography
  • 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.5. X rays
  • 4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.6. Ultrasound
  • 4.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.7. Magnetic Resonance Imaging
  • 4.7.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.8. Nuclear Medicine
  • 4.8.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Coronary Heart Disease Diagnostic Imaging Market: Regional Estimates & Trend Analysis by Country, Application, and End-use

• 5.1. Global Coronary Heart Disease Diagnostic Imaging Market: Regional Dashboard
• 5.2. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 5.3. North America
  • 5.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.3.2. U.S.
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. U.S. market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Key country dynamics
    • 5.3.3.2. Regulatory framework/ reimbursement structure
    • 5.3.3.3. Competitive scenario
    • 5.3.3.4. Canada market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.3.4. Mexico
    • 5.3.4.1. Key country dynamics
    • 5.3.4.2. Regulatory framework/ reimbursement structure
    • 5.3.4.3. Competitive scenario
    • 5.3.4.4. Mexico market estimates and forecast, 2021 - 2033 (USD Million)
• 5.4. Europe
  • 5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.4.2. UK
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. UK market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.4.3. Germany
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. Germany market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.4.4. France
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. France market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.4.5. Italy
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Italy market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.4.6. Spain
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Regulatory framework/ reimbursement structure
    • 5.4.6.3. Competitive scenario
    • 5.4.6.4. Spain market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key country dynamics
    • 5.4.7.2. Regulatory framework/ reimbursement structure
    • 5.4.7.3. Competitive scenario
    • 5.4.7.4. Sweden market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.4.8. Norway
    • 5.4.8.1. Key country dynamics
    • 5.4.8.2. Regulatory framework/ reimbursement structure
    • 5.4.8.3. Competitive scenario
    • 5.4.8.4. Norway market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.4.9. Denmark
    • 5.4.9.1. Key country dynamics
    • 5.4.9.2. Regulatory framework/ reimbursement structure
    • 5.4.9.3. Competitive scenario
    • 5.4.9.4. Denmark market estimates and forecast, 2021 - 2033 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.5.3. Japan
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. Japan market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.5.4. India
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. India market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.5.5. Australia
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. Australia market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Thailand market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.5.7. South Korea
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Regulatory framework/ reimbursement structure
    • 5.5.7.3. Competitive scenario
    • 5.5.7.4. South Korea market estimates and forecast, 2021 - 2033 (USD Million)
• 5.6. Latin America
  • 5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.6.2. Brazil
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Brazil market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.6.3. Argentina
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. Argentina market estimates and forecast, 2021 - 2033 (USD Million)
• 5.7. MEA
  • 5.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.7.3. South Africa
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. South Africa market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.7.4. UAE
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. UAE market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.7.5. Kuwait
    • 5.7.5.1. Key country dynamics
    • 5.7.5.2. Regulatory framework/ reimbursement structure
    • 5.7.5.3. Competitive scenario
    • 5.7.5.4. Kuwait market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
  • 6.1.1. Key company market share analysis, 2025
  • 6.1.2. GE Healthcare
    • 6.1.2.1. Company overview
    • 6.1.2.2. Financial performance
    • 6.1.2.3. End-use benchmarking
    • 6.1.2.4. Strategic initiatives
  • 6.1.3. Koninklijke Philips
    • 6.1.3.1. Company overview
    • 6.1.3.2. Financial performance
    • 6.1.3.3. End-use benchmarking
    • 6.1.3.4. Strategic initiatives
  • 6.1.4. Siemens Healthineers AG
    • 6.1.4.1. Company overview
    • 6.1.4.2. Financial performance
    • 6.1.4.3. End-use benchmarking
    • 6.1.4.4. Strategic initiatives
  • 6.1.5. Fujifilm Sonosite, Inc.
    • 6.1.5.1. Company overview
    • 6.1.5.2. Financial performance
    • 6.1.5.3. End-use benchmarking
    • 6.1.5.4. Strategic initiatives
  • 6.1.6. Canon Medical Systems Corporation
    • 6.1.6.1. Company overview
    • 6.1.6.2. Financial performance
    • 6.1.6.3. End-use benchmarking
    • 6.1.6.4. Strategic initiatives
  • 6.1.7. Samsung Medison Co. Ltd
    • 6.1.7.1. Company overview
    • 6.1.7.2. Financial performance
    • 6.1.7.3. End-use benchmarking
    • 6.1.7.4. Strategic initiatives
  • 6.1.8. Shimadzu Corporation
    • 6.1.8.1. Company overview
    • 6.1.8.2. Financial performance
    • 6.1.8.3. End-use benchmarking
    • 6.1.8.4. Strategic initiatives
  • 6.1.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
    • 6.1.9.1. Company overview
    • 6.1.9.2. Financial performance
    • 6.1.9.3. End-use benchmarking
    • 6.1.9.4. Strategic initiatives
  • 6.1.10. Arineta Ltd
    • 6.1.10.1. Company overview
    • 6.1.10.2. Financial performance
    • 6.1.10.3. End-use benchmarking
    • 6.1.10.4. Strategic initiatives
  • 6.1.11. Esaote SpA
    • 6.1.11.1. Company overview
    • 6.1.11.2. Financial performance
    • 6.1.11.3. End-use benchmarking
    • 6.1.11.4. Strategic initiatives